Society of Hematologic Oncology Seventh Annual Meeting (SOHO 2019)
T

MRD in Multiple Myeloma Isn't Ready for Prime Time: More Patients Can Achieve CR, MRD- Patients Have Better Survival, Many MRD Related Specifics Need to Be Defined

By Society of Hematologic Oncology Seventh Annual Meeting (SOHO 2019) FEATURING Thomas Martin
November 18, 2019
0 Comments
Login to view comments. Click here to Login

Related Content

AUTOPLAY
PeerView Oncology

Mapping the New Era in CLL Management: Precision Medicine and Patient Pe...

Fri, Dec 4, 2020
See 1 other
19:57
Moffitt Cancer Center

Efficacy Analysis of Anti-CD38 in R/R Multiple Myeloma: What Is the Bene...

Feat. K. Shain
10:37
Moffitt Cancer Center's 16th Annual Clinical Breakthroughs & Challenges in Hematologic Malignancies

State of the Art in the Management of Multiple Myeloma: Smoldering MM, I...

Feat. K. Shain
17:59
Parameswaran Hari

Delivering the Best Initial Treatment for Myeloma: Induction Therapy and...

09:20
UNMC 2020 Lymphoma Study Group & Hematology Highlights: A Post ASH Review

Curative Strategy for High-Risk Smoldering Myeloma, Consolidation Therap...

Feat. A. Rosko
25:51
KU ASH 2018 Review: Current Updates in Hematologic Diseases

MM - Overview of Trials Presented at ASH 2018

Feat. A. Abdallah
26:18
Morie Gertz

Treatment of Relapsed Myeloma: Overview of Approved Drugs, mSMART Classi...

08:15
2018 Pan Pacific Lymphoma Conference

Evolution of Myeloma Induction Regimens

Feat. S. Holstein
09:00
5th Annual West Oncology Conference at Graceland: Advances in the Business of Science of Oncology

Treatment Options in R/R Multiple Myeloma: Tips for Selecting Among the ...

Feat. J. Berdeja
12:03
Andrew Cowan

BCMA CAR-T + Gamma Secretase Inhibitor Appear to Be Well Tolerated in R/...

12:16
Society of Hematologic Oncology Seventh Annual Meeting (SOHO 2019)

Discrepancy Between Real World vs. Clinical Trial Data in Relapsed/Refra...

Feat. M. Dimopoulos
13:27
Shaji Kumar

Evolving Concepts in the Diagnosis and Risk Stratification of Myeloma

08:40
Surbhi Sidana

Duration of Complete Response Impacts Overall Survival in Multiple Myeloma

09:50
Nina Shah

Maximizing the Initial Gains in Myeloma Therapy: Consolidation and Maint...

19:41
Peter Voorhees

Approach to the Patient with Refractory & Multiple Relapsed Multiple Mye...

06:12
Indy Hematology Review

Targeting Mutations in Myeloma with Venetoclax and Development of the Fi...

Feat. K. Anderson
10:30
Society of Hematologic Oncology Sixth Annual Meeting (SOHO 2018)

Next Questions in Myeloma: Biology, Smoldering Myeloma, High-risk, MRD, ...

Feat. S. Jagannath
15:02
Krina Patel

Clinical Trials in Myeloma in 2018

15:47
Society of Hematologic Oncology Sixth Annual Meeting (SOHO 2018)

Myeloma State of the Art Update: Bone Disease, MRD Assessment, How to Ma...

Feat. S. Lonial
15:31
UNMC 2020 Lymphoma Study Group & Hematology Highlights: A Post ASH Review

ASH 2019 Relapsed Myeloma Highlights: Can Biomarkers Predict Response to...

Feat. A. Rosko
15:11
Ajay Nooka

Early Relapse: Choosing Among Different Second Line Regimens in Myeloma